MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors

Bone Reports · Elsevier

Аннотация

Publication date: September 2026 Source: Bone Reports, Volume 30 Author(s): G. Mammone, R. Coropciuc, T. Van den Wyngaert, R. Jacobs, P. Bossier, C. Kerkhofs, L. Wijnen, S. Meerschaert, E. Vissenaekens, P.M. Clement, O. Bechter, P.R. Debruyne, A. Laenen, B. Beuselinck

Читать у издателя →

Похожие статьи